Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Bertrand Coiffier, Stéphane Lepretre, Lars Møller Pedersen, Ole Gadeberg, Henrik Fredriksen, Marinus H J van Oers, James Wooldridge, Janusz Kloczko, Jerzy Holowiecki, Andrzej Hellmann, Jan Walewski, Mimi Flensburg, Jørgen Petersen, Tadeusz Robak

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Udgivelsesdato: 2008-Feb-1
OriginalsprogEngelsk
TidsskriftBlood
Vol/bind111
Udgave nummer3
Sider (fra-til)1094-1100
Antal sider6
ISSN0006-4971
DOI
StatusUdgivet - 1. feb. 2008

Fingeraftryk Dyk ned i forskningsemnerne om 'Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study'. Sammen danner de et unikt fingeraftryk.

Citationsformater